Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598934 (
tumor growth
)
58,965
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Voltage-gated potassium (Kv) channels are known to be involved in cancer development and cancer cell proliferation.
KV9.3
, an electronically silent subunit, forms heterotetramers with KV2.1 in excitable cells and modulates its electrophysiological properties. However, the role of
KV9.3
alone in non-excitable cancer cells has not been studied. Here, we evaluated the effect of silencing
KV9.3
on cancer cell proliferation in HCT15 colon carcinoma cells and A549 lung adenocarcinoma cells. We confirmed the expression of
KV9.3
mRNA in HCT15 and A549 cells and showed that silencing
KV9.3
using small interfering RNA caused G0/G1 cell cycle arrest and alterations in cell cycle regulatory proteins in both HCT15 and A549 cells without affecting apoptosis. Also, stable knockdown of
KV9.3
expression using short-hairpin RNA inhibited
tumor growth
in SCID mouse xenograft model. Using a bioinformatics approach, we identified Sp1 binding sites in the promoter region of the gene encoding
KV9.3
. We further found that Sp1 bound to this region and showed that the Sp1 inhibitor, mithramycin A, induced a concentration-dependent decrease in
KV9.3
expression. Taken together, these data suggest that knockdown of
KV9.3
inhibits proliferation in colon carcinoma and lung adenocarcinoma cell lines and may be regulated by Sp1.
...
PMID:Silencing of voltage-gated potassium channel KV9.3 inhibits proliferation in human colon and lung carcinoma cells. 2592 37
